BNF 84 (British National Formulary) September 2022-March 2023: 84: September 2022 - March 2023

Product Information

The new edition (BNF 85) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines. Antibacterials for the prevention of secondary cases of diphtheria, and addition of guidance for the prevention of intra-uterine infection in preterm prelabour rupture of membranes Dexmedetomidine: clinical trial finds increased risk of mortality in intensive care unit patients aged 65 years or younger Blood Results in Clinical Practice: A Practical Guide to Interpreting Blood Test Results - 2nd ed. (2019) We may be able to source and supply a paper copy in exceptional circumstances, from surplus BNFs distributed to other parts of the NHS. Please register your interest in receiving a copy via the online form at: https://www.snapsurveys.com/wh/s.asp?k=153553886772

Potassium permanganate: inadvertent oral administration of potassium permanganate [National Patient Safety Alert advice] Authoritative, independent guidance on best practice enabling you to select safe and effective medicinesNetildex® (dexamethasone with netilmicin) for local treatment of eye inflammation and bacterial infection

Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error Topiramate (Topamax®): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure Maximum daily doses added for colecalciferol and ergocalciferol in the treatment of vitamin D deficiency Hydroxychloroquine sulfate: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions

You may also like…

Physical Examination Procedures for Advanced Practitioners and Non-Medical Prescribers - 2nd ed. (2015) Haloperidol (Haldol®): reminder of risks when used in elderly patients for the acute treatment of delirium Denosumab (Prolia®): should not be used in patients under 18 years due to the risk of serious hypercalcaemia Ivacaftor, tezacaftor, elexacaftor (Kaftrio®▼) in combination with ivacaftor (Kalydeco®): risk of serious liver injury; updated advice on liver function testing Methylphenidate hydrochloride long-acting (modified-release) preparations: caution if switching between products due to differences in formulations